CoChat
Cited by 171

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Pancreatic Cancer Surveillance and Survival of High-Risk Individuals

Open access
Blackford, Amanda L., Canto, Marcia Irene, Dbouk, Mohamad, Hruban, Ralph H., Katona, Bryson W., Chak, Amitabh, Brand, Randall E., Syngal, Sapna, Farrell, James, Kastrinos, Fay, Stoffel, Elena M., Rustgi, Anil, Klein, Alison P., Kamel, Ihab, Fishman, Elliot K., He, Jin, Burkhart, Richard, Shin, Eun Ji, Lennon, Anne Marie, Goggins, Michael · 2024 · JAMA Oncology

Abstract

Importance: Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease with increasing incidence. The majority of PDACs are incurable at presentation, but population-based screening is not recommended. Surveillance of high-risk individuals for PDAC may lead to early detection, but the survival benefit is unproven. Objective: To compare the survival of patients with surveillance-detected PDAC with US national data. Design, Setting, and Participants: This comparative cohort study was conducted in multiple US academic medical centers participating in the Cancer of the Pancreas Screening program, which screens high-risk individuals with a familial or genetic predisposition for PDAC. The comparison cohort comprised patients with PDAC matched for age, sex, and year of diagnosis from the Surveillance, Epidemiology, and End Results (SEER) program. The Cancer of the Pancreas Screening program originated in 1998, and data collection was done through 2021. The data analysis was performed from April 29, 2022, through April 10, 2023. Exposures: Endoscopic ultrasonography or magnetic resonance imaging performed annually and standard-of-care surgical and/or oncologic treatment. Main Outcomes and Measures: Stage of PDAC at diagnosis, overall survival (OS), and PDAC mortality were compared using descriptive statistics and conditional logistic regression, Cox proportional hazards regression, and competing risk regression models. Sensitivity analyses and adjustment for lead-time bias were also conducted. Results: A total of 26 high-risk individuals (mean [SD] age at diagnosis, 65.8 [9.5] years; 15 female [57.7%]) with PDAC were compared with 1504 SEER control patients with PDAC (mean [SD] age at diagnosis, 66.8 [7.9] years; 771 female [51.3%]). The median primary tumor diameter of the 26 high-risk individuals was smaller than in the control patients (2.5 [range, 0.6-5.0] vs 3.6 [range, 0.2-8.0] cm, respectively; P < .001). The high-risk individuals were more likely to be diagnosed with a lower stage (stage I, 10 [38.5%]; stage II, 8 [30.8%]) than matched control patients (stage I, 155 [10.3%]; stage II, 377 [25.1%]; P < .001). The PDAC mortality rate at 5 years was lower for high-risk individuals than control patients (43% vs 86%; hazard ratio, 3.58; 95% CI, 2.01-6.39; P < .001), and high-risk individuals lived longer than matched control patients (median OS, 61.7 [range, 1.9-147.3] vs 8.0 [range, 1.0-131.0] months; 5-year OS rate, 50% [95% CI, 32%-80%] vs 9% [95% CI, 7%-11%]). Conclusions and Relevance: These findings suggest that surveillance of high-risk individuals may lead to detection of smaller, lower-stage PDACs and improved survival.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jamaoncol.2024.1930

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 25 references

Cited by

See all 171

Metadata

Authors
Blackford, A. L., Canto, M. I., Dbouk, M., Hruban, R. H., Katona, B. W., Chak, A., Brand, R. E., Syngal, S., Farrell, J., Kastrinos, F., Stoffel, E. M., Rustgi, A., Klein, A. P., Kamel, I., Fishman, E. K., He, J., Burkhart, R., Shin, E. J., Lennon, A. M., & Goggins, M.
Venue
JAMA Oncology
Published
2024-08-01
Volume
10
Issue
8
Pages
1087
ISSN
2374-2437 (ISSN-L)
OpenAlex
W4400281056
Cited by
171
References
25
FWCI
26.24
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pancreatic Cancer Surveillance and Survival of High-Risk Individuals. https://app.cochat.ai/papers/10.1001/jamaoncol.2024.1930
The paper
Blackford, A. L., Canto, M. I., Dbouk, M., Hruban, R. H., Katona, B. W., Chak, A., Brand, R. E., Syngal, S., Farrell, J., Kastrinos, F., Stoffel, E. M., Rustgi, A., Klein, A. P., Kamel, I., Fishman, E. K., He, J., Burkhart, R., Shin, E. J., Lennon, A. M., & Goggins, M. (2024). Pancreatic Cancer Surveillance and Survival of High-Risk Individuals. JAMA Oncology. https://doi.org/10.1001/jamaoncol.2024.1930

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.